BEZAFIBRATE

Class: Antilipemic Agent, Fibric Acid

Indications: Adjunct to diet and other therapeutic measures for treatment of type IIa and IIb mixed hyperlipidemia, to regulate lipid and apoprotein levels (reduce serum TG, LDL-cholesterol, and apolipoprotein B, increase HDL-cholesterol and apolipoprotein A); treatment of adult patients with high to very high triglyceride levels (Fredrickson classification type IV and V hyperlipidemias) who are at high risk of sequelae and complications from their dyslipidemia.

Dosage: Dyslipidemia: Oral: 400 mg once daily

Dosing: Renal Impairment
Cl\text{cr} \geq 60 \text{ mL/minute}: No dosage adjustment required
Cl\text{cr} < 60 \text{ mL/minute} or S\text{cr} > 1.5 \text{ mg/dL}: Use is contraindicated
Dialysis: Use is contraindicated.

Dosing: Hepatic Impairment
Use is contraindicated in hepatic impairment.

Available dosage form in the hospital: 200MG TAB

Common side effect: Frequency not always defined.
Central nervous system: Headache, dizziness, insomnia.
Dermatologic: Pruritus, eczema, erythema, urticaria
Gastrointestinal: Gastritis, flatulence, dyspepsia.
Hepatic: ALT increased, AST increased
Neuromuscular & skeletal: CPK increased

Pregnancy Implications: Use is contraindicated in pregnant women. Embryotoxicity has occurred in animals at toxic doses. Therapy should be discontinued in women who become pregnant during therapy. Women planning pregnancy should discontinue bezafibrate several months before conception and women of childbearing potential should employ effective birth control methods.